PACB - December 27, 2020

Pacific Biosciences of California is a biotech company that develops and manufactures systems for gene sequencing and is currently the largest position in the ARK Genomic Revolution ETF which is the best performing ETF for ARK. The next big change to healthcare will be the ability to eliminate genetic diseases and prevent certain cancers due to the ability to genetically modify humans. Kathie Wood believes stocks related to the genetic analysis and genetic engineering industry have the potential to grow even faster than stocks related to the electric vehicle industry and clean energy industry in the next 5 years. The TAM is expected to increase 6.6x from 2019 to 2025. PACB recently proved through a Precision FDA Challenge that their equipment is more reliable with the fewest errors when compared to their competitors such as Illumina and ONT PEPPER. They have 81.67% institutional ownership showing strong confidence in the company’s future. PACB recently raised $93M of capital in August 2020.